Pfizer has struck a deal to acquire Metsera, a biotech focused on obesity and cardiometabolic therapeutics, for $4.9 billion upfront with additional milestone payments potentially raising the value to $7.3 billion. This move bolsters Pfizer’s weight loss pipeline, including injectable and oral GLP-1 receptor agonists and amylin analogs targeting obesity and metabolic diseases. Metsera's lead candidates and novel formulations offer potential dosing and tolerability advantages over existing treatments. The acquisition secures Pfizer’s strategic positioning amid intense competition in obesity drug development and follows a period of struggles with its own internal assets in this space.